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Objectives: This study assessed the determinants of urinary output response to furosemide in 
acute kidney injury; specifically, whether the response is related to altered pharmacokinetics 
or pharmacodynamics.  
Design: Prospective cohort. 
Setting: Tertiary intensive care unit. 
Patients: Thirty critically ill patients with acute kidney injury without preexisting renal 
impairment or recent diuretic exposure. 
Intervention: A single dose of IV furosemide.  
Measurements and Main Results: Baseline markers of intravascular volume status were 
obtained prior to administering furosemide. Six-hour creatinine clearance, hourly 
plasma/urinary furosemide concentrations, and hourly urinary output were used to assess 
furosemide pharmacokinetic/pharmacodynamic parameters. Of 30 patients enrolled, 11 had 
stage-1 (37%), nine had stage-2 (30%) and 10 had stage-3 (33%) Acute Kidney Injury 
Network acute kidney injury. Seventy-three percent were septic, 47% required 
norepinephrine, and 53% were mechanically ventilated. Urinary output doubled in 20 patients 
(67%) following IV furosemide. Measured creatinine clearance was strongly associated with 
the amount of urinary furosemide excreted and was the only reliable predictor of the urinary 
output after furosemide (area under the receiver-operating-characteristic curve, 0.75; 95% CI, 
0.57-0.93). In addition to an altered pharmacokinetics (p<0.01), a reduced pharmacodynamic 
response to furosemide also became important when creatinine clearance was reduced to less 
than 40ml/min/1.73m
2
 (p=0.01). Acute kidney injury staging and markers of intravascular 
volume, including central venous pressure, brain-natriuretic-peptide concentration and 




Conclusions: The severity of acute kidney injury, as reflected by the measured creatinine 
clearance, alters both pharmacokinetics and pharmacodynamics of furosemide in acute 
kidney injury, and was the only reliable predictor of the urinary output response to 
furosemide in acute kidney injury. 







Acute kidney injury (AKI) is an increasingly common cause and complication of 
hospital admission and is associated with significant independent morbidity and mortality (1). 
AKI affects up to 30-50% of critically ill patients, and in the 5% of those requiring renal 
replacement therapy (RRT), mortality rates are up to 50% (2). Despite this, there remains 
very little specific therapy that can reduce morbidity and mortality in AKI (3). Evidence 
suggests that non-oliguric AKI, either spontaneously or in response to diuretics, is associated 
with a better prognosis than oliguric AKI (4,5). Because oliguria is a risk factor for poor 
outcomes in AKI and also makes fluid and electrolyte management more difficult, many 
clinicians use large doses of furosemide – a potent loop diuretic – to increase urine output in 
AKI (6). Furosemide blocks the activities of the Na-K-Cl2 co-transporters which may reduce 
the metabolic demand on the loop of Henle. As such, furosemide has been used by some 
clinicians in an attempt to reduce the progression of AKI. 
The traditional way of managing AKI with intravenous (IV) furosemide may stem 
from a lack of understanding about the determinants of urinary output response to 
furosemide, and whether the pharmacokinetics / pharmacodynamics (PK/PD) of furosemide 
are altered in AKI. Furosemide PK/PD studies in human AKI have not been performed; this 
may, in part, be due to the fact that standardised definitions of AKI were not available until 
recently (7,8). Current dosing strategies are therefore commonly based on PK/PD studies 
performed in patients with severe chronic renal failure, renal transplants, or nephrotic 
syndrome (9). In patients with severe chronic renal impairment, although the potency of 
furosemide is reduced (a given dose of furosemide results in a smaller diuresis as reduced 
renal blood flow means less furosemide is able to be secreted into the lumen of the proximal 
tubules i.e. a PK limitation) its efficacy in inducing diuresis (reflected by maximal urinary 
sodium excretion) remains similar to patients with normal renal function (i.e. furosemide PD 
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remains normal) (9). As such, large doses of furosemide have been recommended to induce 
diuresis in patients with severe chronic renal impairment (9), and many clinicians have 
extrapolated this recommendation to patients in AKI.  
It is possible that furosemide PK/PD may be different between patients with AKI and 
chronic renal impairment (10). Administering large doses of furosemide in AKI may be 
harmful, with possible adverse effects including ototoxicty and increased risk of renal 
impairment (11,12). In addition, the unsuccessful implementation of furosemide therapy in 
AKI may delay RRT, and this has been associated with increased mortality (13,14). In this 
study, we aimed to assess the determinants of the urinary output response to IV furosemide in 
patients with AKI, including the relative contributions of PK and PD factors and how these 
may be altered in relation to the severity of AKI.  
 
Materials and Methods 
After obtaining ethics approval (EC2011/130) and written informed consent from all 
patients or from their next-of-kin, 30 patients admitted to the high dependency and intensive 
care units of Royal Perth Hospital, between March 2013 and October 2014, were 
prospectively recruited. Patients with AKI according to the Acute Kidney Injury Network 
(AKIN) criteria (8)
 
were eligible for recruitment if they were judged by their treating 
intensivist to require a dose of IV furosemide to increase urine output. Only patients without 
pre-existing chronic kidney disease were eligible. More detailed inclusion and exclusion 
criteria are detailed in Supplemental Digital Content S1 (15,16).  
 
Study Protocol 
Demographic data recorded for each patient included height, weight, age, diagnosis, 
comorbidities, AKIN AKI staging, Acute Physiology and Chronic Health Evaluation 
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(APACHE) II and Sequential Organ Failure Assessment (SOFA) scores. In addition, peak 
plasma urea and creatinine concentrations during hospital admission, plasma urea and 
creatinine concentrations on hospital discharge (or death), requirement for and duration of 
RRT, and hospital mortality were recorded. Continuous veno-venous hemodiafiltration was 
the only mode of RRT used for the study patients. 
The dose of IV furosemide administered to each patient as a bolus, as well as any 
intravenous fluid administration during the study period was determined by the treating 
intensivist. Physiological measurements were performed at baseline (immediately prior to 
administration of IV furosemide; time zero [T0]) and hourly for six hours following 
furosemide (T1-6). The data collected at each time point are listed in Supplemental Digital 
Content S2. Although plasma creatinine concentration is frequently used to quantify renal 
function and the severity of renal impairment, it can be difficult to interpret in patients with 
unstable renal function (17). Two-, four- and six-hour creatinine clearance (CrCl) have, 
however, been shown to closely correlate with 24-hour CrCl for diagnosis of AKI (18,19). 
Because six-hour CrCl is not affected by a single dose of furosemide (20), we chose to 
measure six-hour CrCl (using T6 plasma creatinine concentration and the urine produced 
between T1 and T6) as a marker of renal function in this study.  
As a sensitivity analysis, the relationship between the measured six-hour CrCl and 
baseline CrCl (based on T0 urine output, plasma and urinary creatinine concentration in the 
hour immediately before the administration of furosemide) was assessed, and found to 
correlate with each other closely (r=0.79, 95% CI: 0.60-0.90; p<0.01). In this study, 
furosemide concentration was measured by ultra-high performance liquid chromatography-
mass spectrometry with a Kinetex XB-C18 column (Phenomenex, Torrence, CA) on a 
Shimadzu Nexera X2 system coupled to a Shimadzu LCMS-8030 triple quadrupole mass 





A description of the study sample size calculation is provided in Supplemental 
Digital Content S3 (21). In the univariate analyses, patients were considered to be 
‘responders’ if the ratio of their urine output in the six hours post- vs. pre-furosemide was 
greater than two (i.e. cumulative urine output in the six hours following furosemide / 
cumulative urine output in the six hours preceding furosemide >2) (4). As a sensitivity 
analysis, we assessed whether the performance of the predictors was similar by defining 
‘responders’ using an absolute amount of urine output >100ml/hr for at least two hours 
during the six-hour period after IV furosemide (22). These end-points were used because they 
have been shown to predict risk of requiring subsequent RRT in patients with AKI in 
previous studies (4,22). Baseline characteristics were compared between responders and non-
responders using Mann-Whitney U, Chi-square or Fisher’s exact test as appropriate.  
Six-hour CrCl and baseline CrCl were calculated, as well as fractional urinary 
excretion of sodium (FENa) before and after furosemide. Total urinary sodium excretion was 
calculated by multiplying urine sodium concentration in the cumulative urine collected over 
six hours with the total volume of urine collected over the same period. Hourly plasma and 
urinary furosemide concentrations were used as an index of furosemide PK, and urine output 
per microgram of urinary furosemide excretion per hour was used as a marker of PD.  
General linear modelling with repeated measures was used to compare plasma 
furosemide concentrations, urine furosemide excretion, and urine output over the six hours 
following furosemide between patients with different severity of AKI. A linear mixed model 
analysis (with random effects of subject and CrCl) was used to assess the independent effects 
of furosemide PK/PD on urinary output response to IV furosemide after confirming no 
deviations from normality by visual inspection of the residual plots. For all multivariate 
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) for ease of clinical 
interpretation. Finally, a restricted analysis was conducted on the group of patients who had 
received IV 40mg furosemide (n=23) to assess whether the results were affected by different 
doses (despite adjustment by the plasma furosemide concentrations). 
 
Results 
Baseline characteristics (Supplemental Digital Content S4) 
Thirty patients (median age 58 years, interquartile range [IQR] 46-75) with a median 
APACHE II score of 23 (IQR 18-29) and a median SOFA score of 6 (IQR 5-10) were 
recruited. Sepsis was present in 73% of patients, and 33% had undergone surgery in the seven 
days prior to recruitment. On the day of testing, 11 patients (37%) had stage 1, nine patients 
(30%) had stage 2 and ten patients (33%) had stage 3 AKIN AKI. The median time from 
onset of AKI to enrolment was 43 hours (IQR 24-75). 
 
Clinical predictors of urine output response 
Twenty patients (67%) were ‘responders’, with a median increase in urine output of 
200% (IQR 140-650%), compared to ten ‘non-responders’ who only increased their urine 
output by 30% (IQR -30 to 70%) in the six hours following a single bolus dose (20-80mg) of 
IV furosemide (Supplemental Digital Content S5). The most important clinical predictor of 
the urinary output response to IV furosemide was the measured CrCl (area under the receiver-
operating-characteristic [ROC] curves for measured six-hour CrCl and baseline CrCl to 
predict a doubling of urinary output after furosemide were 0.75, 95% CI: 0.57-0.93, and 0.78, 
95% CI: 0.59-0.97, respectively). ROC curves for measured six-hour CrCl and serum 
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creatinine to predict a doubling of urinary output after furosemide are presented in 
Supplemental Digital Content S6. 
In the sensitivity analysis, using the alternative definition of response to furosemide, 
20 patients were considered as ‘responders’. Again, the measured CrCl was the most 
important predictor (area under the ROC curves for measured six-hour CrCl and baseline 
CrCl to predict urine output >100ml/hr for at least two hours after furosemide were 0.94, 
95% CI: 0.83-1.04, and 0.89, 95% CI: 0.72-1.06, respectively). 
There was no significant difference in plasma furosemide concentrations between 
patients with different levels of CrCl (p=0.11), but as CrCl progressively reduced there was a 
corresponding reduction in amount of urinary furosemide (p<0.01) as well as volume of urine 
excreted (p<0.01) (Figs. 1A-C). As expected, CrCl was strongly associated with urinary 
sodium excretion following furosemide (p<0.01; Supplemental Digital Content S7). AKIN 
AKI staging at the time of study enrolment and commonly used markers of tissue perfusion 
or intravascular volume status, including baseline plasma lactate concentrations, fractional 
urinary sodium excretion, central venous pressure, brain-natriuretic-peptide concentrations, 
and plethysmographic-variability-index were not predictive of urinary output response to 
furosemide in AKI (Supplemental Digital Content S4). The subsequent renal outcomes of 
the responders and non-responders to IV furosemide are described in Supplemental Digital 
Content S5. 
 
Altered PK/PD of furosemide in AKI 
The severity of AKI - as described by the measured CrCl - had a linear relationship 
with the amount of furosemide excreted in the urine (r=0.65, 95% CI: 0.38-0.82; p<0.01; Fig. 
2). In patients with more severe AKI, renal furosemide clearance was reduced and plasma 
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half-life was longer. The changes in furosemide PK between patients with different severity 
of AKI are summarized in Table 1 (23). 
In addition to an altered PK, there was also an altered PD (urinary output) response in 
patients with severe AKI (Fig. 3), as evidenced by a lower hourly urine output per microgram 
of furosemide excreted into the urine in patients with CrCl <20ml/min/1.73m
2
. This result 
was confirmed and quantified by the linear mixed model (Table 2). When CrCl was 
>40ml/min/1.73m
2
, the urine output response was primarily determined by the amount of 
furosemide excreted into the urine (i.e. a PK limitation) (p<0.01). With moderately severe 
AKI (CrCl 20-40ml/min/1.73m
2
), a PD limitation also became important, as evidenced by the 
significant interaction term between CrCl and urinary furosemide excretion (p=0.01). In 
severe AKI (CrCl <20ml/min/1.73m
2
), a PD limitation became an independent factor (in 
addition to PK changes) in determining urinary output response to IV furosemide (p=0.03). 
These results remained unchanged when the analysis was restricted to only those who had 
received 40mg IV furosemide. 
 
Discussion 
This is the first study specifically investigating furosemide PK/PD in patients with 
AKI. In this prospective study of 30 critically ill patients with AKI, the diuretic effect of a 
single bolus dose of IV furosemide was best predicted by measured CrCl. The relative 
importance of PK/PD effects in influencing the urinary response to furosemide differed 
according to the severity of AKI. Commonly used markers of tissue perfusion and 
intravascular volume status were not predictive of the urinary output response. 
Our findings suggested that the severity of AKI has different effects on different parts 
of the renal tubules. Furosemide is a highly protein-bound (>98%), weak organic acid which 
is actively secreted into the urine by organic acid transporters (OATs) in the proximal tubules 
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(24,25). In patients with elevated plasma urea and creatinine concentrations, uremic acids 
may theoretically alter furosemide PK by competing for tubular secretion by OATs (26). 
Recent evidence also suggests that there are substantial structural and functional changes in 
the proximal tubules in AKI (27-29). In addition, there is a loss of epithelial polarity in renal 





the basolateral to apical membrane (28), reducing the sodium gradient available for 
secondary active transport of organic acids and thus urinary furosemide excretion. Our results 
are consistent with these earlier studies and suggest that OATs in the proximal tubules are 
impaired in proportion to the reduction in CrCl, resulting in derangements in furosemide PK 
in AKI. 
AKI has traditionally been defined as acute tubular necrosis, which may in some 
patients include histological evidence of necrosis in the loop of Henle (30,31). Experimental 
models of AKI caused by renal ischemia-reperfusion injury or inflammation also show a 











(27,29). Our results are consistent with these previous studies; while the proximal tubular 
function is impaired in mild AKI, loop of Henle function becomes progressively more 
affected as the severity of AKI increases, resulting in a corresponding PD limitation. Because 
urinary microscopic analysis was not included as part of our study protocol, we could not 
confirm whether those with severe AKI in this study had structural tubular damage or just 
functional impairment in the loop of Henle.  
Our findings have multiple implications for clinicians managing patients with oliguric 
AKI, most importantly when deciding whether or not to administer furosemide and, if so, at 
what dose. Until now, the only evidence to guide dose selection has been based on studies 
performed in patients with chronic renal impairment where large doses of furosemide are 





) it is likely to be possible to increase the diuretic response to 
furosemide if urinary furosemide excretion can be increased, for example by administering 
larger doses or commencing an infusion. However, due to the strong relationship we 
demonstrate between AKI severity and diuretic response, it is likely that once CrCl falls to a 
certain level (e.g. CrCl <20ml/min/1.73m
2
) administration of further furosemide is unlikely 
to induce a significant diuresis due to PD limitations. As a delay in commencing RRT 
increases mortality (13,14), clinicians should be mindful of this PD limitation when 
attempting to induce diuresis in patients with severe AKI. Early referral to a nephrology 
service or intensive care unit of patients with AKI who do not respond to a furosemide 
challenge should be considered (22), particularly for patients with severe AKI being managed 
in facilities without access to RRT. Intravascular volume status had no effect on furosemide 
responsiveness in patients with adequate tissue perfusion; fluid challenges administered in 
this setting with the intention of increasing urine output should be avoided. In addition to 
potentially delaying RRT, excessive fluid administration is associated with many adverse 
effects (32) and may increase the hazards associated with transferring patients to dialysis 
facilities (e.g. acute pulmonary edema).  
The PD limitations in severe AKI are of relevance to studies investigating possible 
protective effects of furosemide. The theoretical mechanism by which furosemide may 
reduce severity of AKI, through reducing metabolic demand on loop of Henle, would require 
relatively intact PK/PD. Our results may thus explain why a beneficial effect of furosemide 
on the progression of AKI has not been shown (33), and why renal outcomes are better in 
those who do respond to furosemide (indicating intact tubular function and milder AKI) 
(4,22). Patients with less severe AKI are likely to be the most suitable candidates for 
enrolment in future randomized controlled trials (RCTs) investigating the ability of 
furosemide to reduce disease progression. As measured CrCl is a more reliable determinant 
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of furosemide PK/PD, perhaps it represents a more suitable recruitment criterion than plasma 
creatinine or AKIN stage for future RCTs on potential benefits of furosemide in early AKI. 
This study has some strengths and limitations. This is the first human study 
examining the furosemide PK/PD in patients with AKI without pre-existing renal impairment 
or recent diuretic exposure, making the interpretation of furosemide PK/PD reliable. 
However, septic shock was a cause of AKI in many of our patients, and it is possible that 
furosemide PK/PD may differ in AKI due to other causes (e.g. hepatorenal syndrome). As we 
used measured CrCl to reflect the severity of AKI, the PK/PD changes we observed should 
not be used to guide treatment decisions based on a calculated CrCl or plasma creatinine due 
to their poor performance under non-steady-state conditions (17). Although this observational 
study allowed different doses of IV furosemide for the study patients based on clinician 
preferences, our data clearly suggests that plasma furosemide concentrations were not as 
important as severity of AKI in determining urinary output response to IV furosemide in AKI 
(Figs. 1A-C). Finally, this pharmacological study was not designed to detect a difference in 
renal outcomes between those with different furosemide PK/PD, and would not detect the 
predictive ability of some less important clinical variables (e.g. norepinephrine requirement) 
(4). Thus, whether using interventions to improve furosemide PK in AKI can improve 
patient-centered outcomes remains unproven. 
 
Conclusions 
CrCl was the most important clinical predictor of the diuretic response to a single 
bolus dose of IV furosemide in patients with AKI. A decrease in measured CrCl was 
associated with progressive changes in furosemide PK/PD, the sequence of which suggests 
that patients with mild AKI are more likely to respond to IV furosemide than those with 
severe AKI. Using large doses of IV furosemide in severe AKI, when both PK and PD of 
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furosemide are altered, is unlikely to induce significant diuresis or prevent acute tubular 
necrosis, and may only delay inevitable dialysis.  
 
Contributors: BIS and KMH collected and analysed data, and drafted the initial manuscript. 
All authors contributed to study design, data interpretation, and manuscript revision. The 
corresponding author (KMH) confirms that he had full access to all study data and final 
responsibility for the decision to submit for publication. 
 
Acknowledgements: We would like to thank Ms Jenny Chamberlain for her advice on the 
data collection process, Ms Linda Gregory for her assistance with the laboratory resources, 







1. Coca SG, Yusuf B, Shlipak MG, Garg AX, Parikh CR: Long-term risk of mortality 
and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. 
Am J Kidney Dis 2009; 53: 961-973. 
2. Murugan R, Kellum JA: Acute kidney injury: what's the prognosis? Nat Rev Nephrol 
2011; 7: 209-217. 
3. Ho KM: Kidney and acid-base.  In: Hopkins PM, Struy MM, Hardman J (Eds). 
Oxford Textbook of Anaesthesia, 1st Edition. Oxford University Press; 2016 (in press). 
4. Ho KM, Walters S, Faulke D, Liang J: Clinical predictors of acute renal replacement 
therapy in critically ill patients with acute renal impairment. Crit Care Resusc 2003; 5: 97-
102. 
5. Morgan DJ, Ho KM: A comparison of nonoliguric and oliguric severe acute kidney 
injury according to the risk injury failure loss end-stage (RIFLE) criteria. Nephron Clin Pract 
2010; 115: c59-65. 
6. Bagshaw SM, Delaney A, Jones D, Ronco C, Bellomo R: Diuretics in the 
management of acute kidney injury: a multinational survey. Contrib Nephrol 2007; 156: 236-
249. 
7. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P: Acute renal failure - 
definition, outcome measures, animal models, fluid therapy and information technology 
needs: the Second International Consensus Conference of the Acute Dialysis Quality 
Initiative (ADQI) Group. Crit Care 2004; 8: R204-212. 
8. Mehta RL, Kellum JA, Shah SV, et al: Acute Kidney Injury Network: report of an 
initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31. 




10. Bonventre JV, Yang L: Cellular pathophysiology of ischemic acute kidney injury. J 
Clin Invest 2011; 121: 4210-4221. 
11. Ho KM, Sheridan DJ: Meta-analysis of frusemide to prevent or treat acute renal 
failure. BMJ 2006; 333: 420. 
12. Solomon R, Werner C, Mann D, D'Elia J, Silva P: Effects of saline, mannitol, and 
furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N 
Engl J Med 1994; 331: 1416-1420. 
13. Karvellas CJ, Farhat MR, Sajjad I, et al: A comparison of early versus late initiation 
of renal replacement therapy in critically ill patients with acute kidney injury: a systematic 
review and meta-analysis. Crit Care 2011; 15: R72. 
14. Leite TT, Macedo E, Pereira SM, et al: Timing of renal replacement therapy initiation 
by AKIN classification system. Crit Care 2013; 17: R62. 
15. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney 
disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266. 
16. Levey AS, Stevens LA, Schmid CH, et al: A new equation to estimate glomerular 
filtration rate. Ann Intern Med 2009; 150: 604-612. 
17.  Endre ZH, Pickering JW, Walker RJ: Clearance and beyond: the complementary roles 
of GFR measurement and injury biomarkers in acute kidney injury (AKI). Am J Physiol 
Renal Physiol 2011; 301: F697-707. 
18. Wilson RF, Soullier G: The validity of two-hour creatinine clearance studies in 
critically ill patients. Crit Care Med 1980; 8: 281-284. 
19. Herrera-Gutierrez ME, Seller-Perez G, Banderas-Bravo E, Munoz-Bono J, Lebron-
Gallardo M, Fernandez-Ortega JF: Replacement of 24-h creatinine clearance by 2-h 
creatinine clearance in intensive care unit patients: a single-center study. Intensive Care Med 
2007; 33: 1900-1906. 
17 
 
20. Lam NP, Kuk JM, Franson KL, Lau AH: Effect of diuretic drugs on creatinine 
clearance determination. Ther Drug Monit 1995; 17: 142-144. 
21. Hammarlund-Udenaes M, Benet LZ: Furosemide pharmacokinetics and 
pharmacodynamics in health and disease--an update. J Pharmacokinet Biopharm 1989; 17: 1-
46. 
22. Chawla LS, Davison DL, Brasha-Mitchell E, et al: Development and standardization 
of a furosemide stress test to predict the severity of acute kidney injury. Crit Care 2013; 17: 
R207. 
23.  Gibaldi M, Perrier D: Noncompartmental Analysis Based on Statistical Moment 
Theory. In: Swarbrick J (Ed). Pharmacokinetics, Second Edition. New York: Marcel Dekker; 
1982: 409-417. 
24. Prandota J, Pruitt AW: Furosemide binding to human albumin and plasma of 
nephrotic children. Clin Pharmacol Ther 1975; 17: 159-165. 
25. Hasannejad H, Takeda M, Taki K, et al: Interactions of human organic anion 
transporters with diuretics. J Pharmacol Exp Ther 2004; 308: 1021-1029. 
26. Rose HJ, O'Malley K, Pruitt AW: Depression of renal clearance of furosemide in man 
by azotemia. Clin Pharmacol Ther 1977; 21: 141-146. 
27. Kunin M, Holtzman EJ, Melnikov S, Dinour D: Urinary organic anion transporter 
protein profiles in AKI. Nephrol Dial Transplant 2012; 27: 1387-1395. 
28. Schmidt C, Hocherl K, Schweda F, Kurtz A, Bucher M: Regulation of renal sodium 
transporters during severe inflammation. J Am Soc Nephrol 2007; 18: 1072-1083. 
29. Calzavacca P, May CN, Bellomo R: Glomerular haemodynamics, the renal 
sympathetic nervous system and sepsis-induced acute kidney injury. Nephrol Dial Transplant 
2014; 29: 2178-2184. 
18 
 
30. Rosen S, Heyman SN: Difficulties in understanding human "acute tubular necrosis": 
limited data and flawed animal models. Kidney Int 2001; 60: 1220-1224. 
31. Rosen S, Stillman IE: Acute tubular necrosis is a syndrome of physiologic and 
pathologic dissociation. J Am Soc Nephrol 2008; 19: 871-875. 
32. Prowle JR, Kirwan CJ, Bellomo R: Fluid management for the prevention and 
attenuation of acute kidney injury. Nat Rev Nephrol 2014; 10: 37-47. 
33. Ho KM, Power BM: Benefits and risks of furosemide in acute kidney injury. 





Table 1. The importance of creatinine clearance in the pharmacokinetics of intravenous 
furosemide in patients with acute kidney injury 







 p value 
Plasma furosemide concentration 
AUC0-6, mg.hr/l
 
5.1 (3.5-6.3) 9.8 (5.2-11.7) 7.4 (5.9-12.4) 0.07 
Urine furosemide excretion, mg 11.7 (8.3-13.9) 8.2 (4.3-11.9) 1.1 (0.2-1.9) <0.01 
CLtotal, l/hr
 
6.7 (5.6-7.7) 3.7 (2.7-5.5) 2.9 (2.3-5.0) 0.02 
CLurine, l/hr
 
2.1 (1.6-2.5) 0.7 (0.4-1.2) 0.1 (0.0-0.2) <0.01 
CLmetabolic, l/hr
 
4.3 (4.0-5.6) 2.9 (2.2-4.2) 2.8 (2.3-4.9) 0.07 
Vd, l/kg
 
0.12 (0.10-0.16) 0.12 (0.11-0.17) 0.12 (0.07-0.21) 0.90 
Vdss, l/kg 0.11 (0.09-0.12) 0.08 (0.06-0.11) 0.06 (0.03-0.10) 0.13 
Half-life, hrs 1.5 (1.2-2.6) 2.3 (1.9-4.4) 2.9 (2.2-4.0) 0.01 
AUC, area under the curve. CL, clearance. CrCl, creatinine clearance. Vd, volume of distribution. ss, steady 
state. 




(23) was used to estimate furosemide’s PK parameters. The logarithmic trapezoidal 
method was used to calculate the area under furosemide’s plasma concentration-time curve (AUC0-6). As plasma 
furosemide concentration was first measured 1 hour following injection, plasma concentration at time 0 was 
extrapolated using the function Ct = C0×e
-kt
 with t = 1 and k (elimination rate constant) calculated from plasma 
concentrations at times 1 and 2. Final AUC0-6 was therefore the sum of ‘measured’ AUC1-6 and ‘extrapolated’ 
AUC0-1. Systemic and renal clearance, and apparent volume of distribution at steady state were estimated from 
AUC0-∞ using the methods described by Gibaldi (23). Metabolic clearance of furosemide was calculated as the 
difference between estimated systemic and renal clearance. Half-life was calculated using the formula t1/2 = 
ln(2)/kel1-6. Comparison between groups performed using Kruskal-Wallis test. 
 
Table 2: Linear mixed model analysis of the relationship between hourly urine output 
(dependent variable) following intravenous furosemide and predictors 
 
Predictor β coefficient 
(95% CI) 
p value 
Intercept 104 (53, 154) <0.01 
Time point 1.3 (-12, 15) 0.85 
Hourly urinary furosemide excretion 0.07 (0.05, 0.08) <0.01 
Hourly plasma furosemide concentration -4.9 (-19, 9.5) 0.50 
Creatinine clearance  0.07 
- <20 ml/min/1.73m2 
- 20-40 ml/min/1.73m2 
- >40 ml/min/1.73m2 
-88 (-167, -9) 





Interaction term: creatinine clearance x hourly urinary furosemide excretion 
- <20 ml/min/1.73m2 
- 20-40 ml/min/1.73m2 
- >40 ml/min/1.73m2 
 
0.02 (-0.15, 0.20) 














Figure 1: Changes in hourly (a) plasma furosemide concentration, (b) urinary furosemide 
excretion and (c) urine output over the six hour period following a single bolus dose of 
intravenous furosemide, stratified by measured creatinine clearance. Error bars signify 95% 










Figure 2: A relatively linear association was present between measured creatinine clearance 
and the total amount of furosemide excreted in urine over the six hour period following a 
single bolus dose of intravenous furosemide. Spearman correlation coefficient 0.80 (95% 






Figure 3: Relationship between hourly urinary output and hourly urinary furosemide 
excretion (in natural logarithmic scale), stratified by measured creatinine clearance (CrCl). 
Trend lines were plotted for each CrCl category using loess regression, and the gradients or 






Supplemental Digital Content 
 
S1 Inclusion and exclusion criteria for recruitment  
 
Inclusion criteria: 
– Patients with acute kidney injury (AKI) (of any stage) according to AKI Network 
criteria 
– Treating intensivist intends to prescribe IV furosemide to increase urine output 
– Arterial, central venous and urinary catheters in situ 
Exclusion criteria: 
– Patients with known chronic kidney disease (CKD) (15) or documented estimated 
glomerular filtration rate (eGFR) <60mL/min (CKD-EPI) (16)
 
in the 3 months prior to 
current hospital admission 
– Treating intensivist intends to prescribe further doses of diuretic medication 
(including furosemide infusion) within the 6 hours required for study sampling 
– Patients who have received intravenous or oral diuretics (including mannitol) in the 
24 hours prior to study enrolment 
– Patients who have received other medications (e.g. fludrocortisone) known to affect 
renal sodium or water excretion in the 24 hours prior to study enrolment 
– Patients with uncontrolled hyperglycaemia (plasma glucose >10mmol/L) 
– Patients receiving renal replacement therapy prior to study enrolment 
– Patients with obstructive uropathy, macroscopic haematuria or intra-abdominal 
hypertension (>20mmHg) 





S2 Description of data collected 
 
Hourly data from T0-6: 
– Heart rate; mean arterial pressure (transduced from intra-arterial catheter); central 
venous pressure; noradrenaline infusion dose; mode of ventilation and mean airway 
pressure; inspired oxygen concentration; hourly urine output; volume and type of fluid 
boluses administered (if any) 
– Arterial blood sample: furosemide concentration 
– Urine sample: furosemide concentration 
 
Additional data at baseline (T0): 
– Plethysmographic variability index (Radical-7, Masimo Corporation, Irvine, 
California); total urine output in the preceding 6 hours 
– Arterial blood sample: pH, partial pressures of oxygen and carbon dioxide, 
bicarbonate, lactate; plasma sodium, potassium, urea, creatinine, albumin, B-type 
natriuretic peptide, C-reactive protein 
– Urine sample: sodium, creatinine 
 
Additional data at T6: 
– Arterial blood sample: plasma sodium, potassium, urea, creatinine 
– Sample of total urine produced during T0-6: sodium, creatinine 
 
Six-hour creatinine clearance (CrCl) measurement: 
 





S3 Sample size calculation 
 
Following an IV dose of furosemide 40mg, the standard deviation of urinary furosemide 
excretion (in milligrams) has been reported to range between 1.8 and 9.5 (21). We have 
previously reported the standard deviation of the ratio of post- vs. pre-furosemide (IV dose 
range 40-120mg; 80% received 40mg) urine output to be 4.2 in patients with AKI who did 
not subsequently require dialysis, and 0.46 in patients who did require dialysis (4). Based on 
this data, the largest sample size that would be required ( = 4.2, x = 1.8) is 32 patients 
(assuming  = 0.05, β = 0.2, and  [difference in regression line gradient to be detected] = 
1.2). However, this is likely to be an over-estimate as the value used for  will be increased 





S4 Differences in baseline characteristics between responders and non-responders to a 
single bolus dose of intravenous furosemide. 
 






Age, years 58 (46-75) 49 (40-74) 65 (53-78) 0.08 
Body weight, kg 89 (73-96) 91 (76-98) 80 (68-94) 0.17 
Male, no. (%) 19 (63) 13 (65) 6 (60) 0.90 
Sepsis
a
, no. (%) 22 (73) 16 (80) 6 (60) 0.38 
Diabetes mellitus, no. (%) 6 (20) 5 (25) 1 (10) 0.63 
Mechanically ventilated, no. (%) 16 (53) 12 (60) 4 (40) 0.45 














APACHE II score 23 (18-29) 22 (16-27) 27 (18-32) 0.23 
SOFA score on day of testing 6 (5-10) 5 (5-9) 9 (5-13) 0.18 
Haemodynamic and biochemical:     
- Heart rate, beats/min 
- MAP, mmHg 
- CVP, mmHg 
- PVI 
- BNP, ng/l 
- CRP, mg/l 
- Albumin, g/l 
- Plasma sodium, mmol/l 
- Plasma urea, mmol/l 
- Plasma creatinine, µmol/l 
- Urine outputb, ml/hr 
- Urine outputc, ml/kg/hr 
- FENa, % 
- Measured CrCld, ml/min/1.73m2 
- Norepinephrine, µg/min 

































































IV furosemide dose (20/40/80mg), no. 6/23/1 4/15/1 2/8/0 0.90 
AKIN, Acute Kidney Injury Network. APACHE, Acute Physiology and Chronic Health Evaluation. BNP, brain 
natriuretic peptide. CrCl, creatinine clearance. CRP, C-reactive protein. CVP, central venous pressure. FENa, 
fractional urinary sodium excretion. MAP, mean arterial pressure. PVI, plethysmographic-variability-index. 
SOFA, Sequential Organ Failure Assessment.  
All values represent median (interquartile range) unless stated otherwise. 
a
 Sepsis was defined as documented infection requiring systemic antibiotic treatment at the time of study 
enrolment.  
b
 Median urine output in the hour immediately prior to IV furosemide. 
c
 Median hourly urine output in the 6 hours prior to IV furosemide. Total urine output in the 6 hours prior to IV 
furosemide was also similar between responders and non-responders (p = 0.88). 
d
 Creatinine clearance measured over a 6-hour period, area under the receiver-operating-characteristic curve for 
measured creatinine clearance to predict a doubling of urinary output after furosemide = 0.75 (95% confidence 
interval [CI] 0.57-0.93). Measured baseline CrCl to predict a doubling of urinary output after furosemide = 0.78 





S5 Differences in outcomes between responders and non-responders to a single bolus 
dose of intravenous furosemide 
 







Urine output ratio after furosemide
a
 2.4 (1.6-3.6) 3.0 (2.4-6.5) 1.3 (0.7-1.7) <0.01 
Urine output after furosemide
b
, l 













, mmol 74 (24-157) 132 (38-184) 24 (1.2-68) 0.01 
FENa after furosemide, % 3.6 (1.9-6.9) 4.0 (2.4-8.1) 2.3 (0.7-4.4) 0.12 
Plasma sodium after furosemide, mmol/l 141 (135-147) 141 (137-147) 143 (133-148) 0.81 
Total urine output on study day, l 2.15 (1.53-3.17) 2.65 (1.65-3.50) 1.71 (0.30-2.13) 0.05 
Peak plasma urea, mmol/l 21 (13-25) 17 (12-24) 22 (18-28) 0.20
c
 





, mmol/l 9 (6-13) 8 (6-11) 11 (5-16) 0.59 
Hospital discharge creatinine
d
, µmol/l 99 (73-147) 99 (77-129) 97 (59-184) 0.75 
Received CRRT, no. (%) 6 (20) 3 (15) 3 (30) 0.37 
Either received CRRT or had a decision 
not for dialysis
e
, no. (%) 
8 (27) 4 (20) 4 (40) 0.38 
ICU mortality, no. (%) 5 (17) 2 (10) 3 (30) 0.30 
Hospital mortality, no. (%) 6 (20) 3 (15) 3 (30) 0.37 
CRRT, continuous renal replacement therapy. FENa, fractional urinary sodium excretion. ICU, intensive care 
unit.  
All values represent median (interquartile range) unless stated otherwise. 
a
 Calculated as: (total urine output in 6 hours following furosemide) / (total urine output in 6 hours preceding 
furosemide) 
b
 Total in the 6 hours following IV furosemide. 
c
 p values for peak plasma urea and creatinine concentrations were 0.06 and 0.76, respectively, when patients 
who eventually needed dialysis were excluded. 
d
 Last recorded value prior to hospital discharge or death. 
e
 Includes all patients who received CRRT as well as patients who required CRRT but did not receive it due to 




S6 Receiver operating characteristic (ROC) curves for measured six-hour creatinine 




Area under ROC curve: 
Measured six-hour CrCl: 0.75 (95% confidence interval: 0.57-0.93), p = 0.03 




S7 Six-hour urinary sodium excretion over two consecutive periods, before and 
immediately after a single bolus dose of intravenous furosemide, stratified by measured 
creatinine clearance. Error bars signify 95% confidence interval.  
 
 
  
 
 
 
